The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
This peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product and human PDE6 alpha', catalog ab5660. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (70-fold) for competitive inhibition of antibody-protein binding reactions.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
5''-cyclic phosphodiesterase subunit alpha''
cGMP phosphodiesterase 6C
Cone cGMP specific 3' 5' cyclic phosphodiesterase subunit alpha'
Cone cGMP-specific 3''
PDE6 alpha prime
Phosphodiesterase 6C cGMP specific cone alpha prime
Involvement in disease
Defects in PDE6C are the cause of cone dystrophy type 4 (COD4) [MIM:613093]. An early-onset cone dystrophy. Cone dystrophies are retinal dystrophies characterized by progressive degeneration of the cone photoreceptors with preservation of rod function, as indicated by electroretinogram. However, some rod involvement may be present in some cone dystrophies, particularly at late stage. Affected individuals suffer from photophobia, loss of visual acuity, color vision and central visual field. Another sign is the absence of macular lesions for many years. Cone dystrophies are distinguished from the cone-rod dystrophies in which some loss of peripheral vision also occurs.
Belongs to the cyclic nucleotide phosphodiesterase family. Contains 2 GAF domains.